Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 12Gastrointestinal 10Thoracic 4Lymphoid 3Sarcoma 2Other hematologic neoplasm 2Gynecologic 2Tumor-Agnostic 1Plasma cell 1Head & Neck 1Genitourinary 1

Conditions

Ovarian Neoplasms 2

Interventions

Paclitaxel 581Carboplatin 527Cisplatin 355Bevacizumab 256pembrolizumab 226Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 126Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 90niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 73Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 56Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enoxaparin × Gynecologic × Clear all
NCT03532139 2025-01-23

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

Beth Israel Deaconess Medical Center

Phase 2 Completed
24 enrolled
Gynecologic

Ovarian Neoplasms

NCT00908960 2017-12-19

MicroTEC

Dana-Farber Cancer Institute

Phase 2 Completed
70 enrolled 9 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡